• Kord M Kober, Melissa Mazor, Gary Abrams, Adam Olshen, Yvette P Conley, Marilyn Hammer, Mark Schumacher, Margaret Chesney, Betty Smoot, Judy Mastick, Steven M Paul, Jon D Levine, and Christine Miaskowski.
• School of Nursing, University of California, San Francisco, California, USA. Electronic address: kord.kober@ucsf.edu.
• J Pain Symptom Manage. 2018 Dec 1; 56 (6): 908-919.e3.

ContextAlthough paclitaxel is one of the most commonly used drugs to treat breast, ovarian, and lung cancers, little is known about the impact of paclitaxel-induced peripheral neuropathy (PIPN) on cancer survivors.ObjectivesThe purposes of this study were to evaluate for differences in demographic and clinical characteristics as well as measures of sensation, balance, upper extremity function, perceived stress, symptom burden, and quality of life (QOL) between survivors who received paclitaxel and did (n = 153) and did not (n = 58) develop PIPN.MethodsPain characteristics associated with PIPN are described in detail. Both subjective and objective measures were used to evaluate the impact of PIPN.ResultsSurvivors with PIPN were significantly older, had a higher body mass index, and a worse comorbidity profile. The duration of PIPN was almost four years, and pain scores were in the moderate range. Compared with survivors without PIPN, survivors with PIPN had a higher number of upper and lower extremity sites that had lost light touch, cold, and pain sensations. Survivors with PIPN had worse upper extremity function, more problems with balance, a higher symptom burden, and higher levels of perceived stress. In addition, survivors with PIPN had worse QOL scores particularly in the domain of physical functioning.ConclusionThe findings from this large descriptive study are the first to document the impact of PIPN on survivors' symptom burden, functional status, and QOL.Copyright © 2018 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

30 keywords...

hide…